DK1663347T3 - Afereseindretning - Google Patents

Afereseindretning

Info

Publication number
DK1663347T3
DK1663347T3 DK04761033T DK04761033T DK1663347T3 DK 1663347 T3 DK1663347 T3 DK 1663347T3 DK 04761033 T DK04761033 T DK 04761033T DK 04761033 T DK04761033 T DK 04761033T DK 1663347 T3 DK1663347 T3 DK 1663347T3
Authority
DK
Denmark
Prior art keywords
apheresis device
apharesis
contacted
plasma
blood
Prior art date
Application number
DK04761033T
Other languages
English (en)
Inventor
Walter Schmidt
Frank Mattner
Original Assignee
Affiris Forschungs & Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663347(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affiris Forschungs & Entwicklungs Gmbh filed Critical Affiris Forschungs & Entwicklungs Gmbh
Application granted granted Critical
Publication of DK1663347T3 publication Critical patent/DK1663347T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • External Artificial Organs (AREA)
DK04761033T 2003-09-12 2004-09-13 Afereseindretning DK1663347T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0144403A AT413336B (de) 2003-09-12 2003-09-12 Apherese-vorrichtung
PCT/AT2004/000311 WO2005025651A1 (de) 2003-09-12 2004-09-13 Apherese-vorrichtung

Publications (1)

Publication Number Publication Date
DK1663347T3 true DK1663347T3 (da) 2008-05-19

Family

ID=34280361

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04761033T DK1663347T3 (da) 2003-09-12 2004-09-13 Afereseindretning

Country Status (16)

Country Link
US (2) US7935252B2 (da)
EP (1) EP1663347B1 (da)
JP (1) JP4509113B2 (da)
CN (1) CN100556472C (da)
AT (2) AT413336B (da)
AU (1) AU2004271651B2 (da)
CA (1) CA2538305C (da)
CY (1) CY1107911T1 (da)
DE (1) DE502004005851D1 (da)
DK (1) DK1663347T3 (da)
ES (1) ES2298789T3 (da)
HK (1) HK1096320A1 (da)
HR (1) HRP20080090T3 (da)
PL (1) PL1663347T3 (da)
PT (1) PT1663347E (da)
WO (1) WO2005025651A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
WO2009082515A1 (en) * 2007-12-21 2009-07-02 Ge Healthcare Bio-Sciences Ab Method for sterilization of chemically activated solid support materials
WO2010014702A1 (en) * 2008-07-29 2010-02-04 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
CN102264411B (zh) * 2008-12-22 2014-10-22 学校法人藤田学园 Aβ除去材料、Aβ除去器和Aβ除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
PL2579042T3 (pl) 2011-10-04 2014-12-31 Affiris Ag Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
AU2015286606A1 (en) * 2014-07-10 2017-01-12 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57103649A (en) * 1980-12-18 1982-06-28 Asahi Chemical Ind Sterilized gamma-globulin fixing column
WO1987001597A1 (fr) 1985-09-19 1987-04-26 Toray Industries, Inc. COLONNE D'EXTRACTION DE beta2-MICROGLOBULINE
DE3853219T2 (de) * 1987-11-20 1995-06-29 Kanegafuchi Chemical Ind Methode zur Entfernung von Serum-Amyloid-Protein.
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JPH06104122A (ja) 1992-09-21 1994-04-15 Matsushita Electric Ind Co Ltd ロータリートランス
JP3161604B2 (ja) * 1994-05-13 2001-04-25 プラズマセレクト ゲーエムベーハー テテロウ 血液中の物質を結合してそれを除去するためのタンパク質を結合させた、無菌かつ発熱物質を含有しないカラム
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
TWI238251B (en) * 2000-07-13 2005-08-21 Anawrhta Biotech Co Ltd In-vitro adsorbing device using immunity
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
CA2538305A1 (en) 2005-03-24
CA2538305C (en) 2011-05-24
CN100556472C (zh) 2009-11-04
EP1663347B1 (de) 2008-01-02
WO2005025651A1 (de) 2005-03-24
ATA14442003A (de) 2005-07-15
AU2004271651B2 (en) 2009-08-06
ATE382383T1 (de) 2008-01-15
ES2298789T3 (es) 2008-05-16
CN1867365A (zh) 2006-11-22
AT413336B (de) 2006-02-15
EP1663347A1 (de) 2006-06-07
US20110166327A1 (en) 2011-07-07
AU2004271651A1 (en) 2005-03-24
US7935252B2 (en) 2011-05-03
PT1663347E (pt) 2008-03-28
HRP20080090T3 (en) 2008-03-31
US20070026029A1 (en) 2007-02-01
DE502004005851D1 (de) 2008-02-14
HK1096320A1 (en) 2007-06-01
JP4509113B2 (ja) 2010-07-21
CY1107911T1 (el) 2013-09-04
JP2007504863A (ja) 2007-03-08
PL1663347T3 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
HK1096320A1 (en) Apheresis device
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
ATE474617T1 (de) Medizinproduktsysteme
DE60328797D1 (de) Blutbehandlungsgerät
DE602005024846D1 (de) Blutdialysator
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
TR200504892A1 (tr) Belirti göstermeyen tüberküloz tedavisi
DK2219642T3 (da) Silibininbestandel til behandling af hepatitis
ATE515280T1 (de) Vorrichtung zur intermittierenden okklusion des koronarsinus
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
TR201001461T1 (tr) Katater klipsi
ATE465977T1 (de) Fluidbehandlungseinrichtung
NO20072285L (no) S-mirtazapin for behandling av hetetokter
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
ATA13602003A (de) Therapeutisches behandlungsgerät
DK1713438T3 (da) Medicinsk sæbe
ITMI20030647A1 (it) Dispositivo per il trattamento di sangue in circolazione extracorporea
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
ITVR20040130A1 (it) Cuscino ortopedico abduttore in particolare per l'immobilizzazione del braccio
ITRM20040047A1 (it) Vaccino per la cura della tubercolosi.
FR2857575B3 (fr) Seringue de securite pour le prelevement de sang
UA3370U (uk) Спосіб лікування центральної хоріоретинальної дистрофії